| 000 | 01956naaaa2200301uu 4500 | ||
|---|---|---|---|
| 001 | https://directory.doabooks.org/handle/20.500.12854/77507 | ||
| 005 | 20220220035517.0 | ||
| 020 | _aintechopen.87640 | ||
| 020 | _a9781789847536 | ||
| 020 | _a9781789847529 | ||
| 020 | _a9781789852011 | ||
| 024 | 7 |
_a10.5772/intechopen.87640 _cdoi |
|
| 041 | 0 | _aEnglish | |
| 042 | _adc | ||
| 072 | 7 |
_aMMG _2bicssc |
|
| 100 | 1 |
_aAditya Parikesit, Arli _4edt |
|
| 700 | 1 |
_aAditya Parikesit, Arli _4oth |
|
| 245 | 1 | 0 | _aDrug Design : Novel Advances in the Omics Field and Applications |
| 260 |
_bIntechOpen _c2021 |
||
| 300 | _a1 electronic resource (158 p.) | ||
| 506 | 0 |
_aOpen Access _2star _fUnrestricted online access |
|
| 520 | _aRight before the COVID-19 pandemic declared by the World Health Organization (WHO), life sciences have incited novel areas of studies that revolutionize the health sector. They are the studies of structural bioinformatics, pharmacogenomics, and metabolomics. The structural bioinformatics field is the very foundation of drug design research, as it provides insight into the molecular simulations and interactions between the biomolecules and the drug candidates. Secondly, pharmacogenomics is the starting point of any efforts in developing personalized medicine. Lastly, metabolomics provides instrumentation to elicit biomarkers for various diseases and health conditions. These studies have enabled current accelerated effort in COVID-19 research, as well as other communicable and non-communicable diseases. | ||
| 540 |
_aCreative Commons _fhttps://creativecommons.org/licenses/by/3.0/ _2cc _4https://creativecommons.org/licenses/by/3.0/ |
||
| 546 | _aEnglish | ||
| 650 | 7 |
_aPharmacology _2bicssc |
|
| 856 | 4 | 0 |
_awww.oapen.org _uhttps://www.intechopen.com/books/9831 _70 _zDOAB: download the publication |
| 856 | 4 | 0 |
_awww.oapen.org _uhttps://directory.doabooks.org/handle/20.500.12854/77507 _70 _zDOAB: description of the publication |
| 999 |
_c63591 _d63591 |
||